Clinical trials: Lipodystrophy
Type 1 Diabetes Mellitus
The Skin Barrier in Users of Diabetes Devices
Diabetes technology (insulin pumps and continuous glucose monitoring) have become standard of care in children with type 1 diabetes.
- Trial name
- StenoLin (NCT06856954)
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Jannet Svensson
Lipodystrophy
Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy
Background: Lipodystrophy is a health problem in which the body does not have enough fat tissue. People with lipodystrophy may not make enough of the hormone leptin. Leptin regulates hunger. Low leptin levels trigger hunger.
- Trial name
- NCT05419037
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
This study involves research about an investigational medicine called metreleptin. The reason for this study is to find out how metreleptin can improve non-alcoholic steatohepatitis or nonalcoholic fatty liver disease associated…
- Conditions
- Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, Lipodystrophy
- Trial name
- NCT01679197
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Familial Partial Lipodystrophy Type 2
Study of Cortisol Metabolism in Familial Partial Lipodystrophy Type 2
Familial partial lipodystrophic syndromes are characterized by an increase in visceral adipose tissue and an atrophy of subcutaneous adipose tissue.
- Trial name
- LIPOCORT (NCT04845165)
- Testing
- Biopsy
- Where
- France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Lille
Insulin Resistance, Hypertriglyceridemia
Novel Therapies for Metabolic Complications of Lipodystrophies
Lipodystrophies represent a therapeutic challenge with regards to the management of the diabetes, insulin resistance, hypertriglyceridemia and fatty liver which frequently present in conjunction with significant adipose tissue…
- Conditions
- Insulin Resistance, Hypertriglyceridemia, Diabetes, Hepatic Steatosis
- Trial name
- NCT00457938
- Testing
- low-fat diet ( Still recruiting ), Diet
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Texas Southwestern Medical Center
Romberg's Disease, Craniofacial Microsomia
Role of Mesenchymal Stem Cells in Fat Grafting
Contour deformity of face causes both functional as well as aesthetic problems for the patient. Fat being an autologous tissue source is considered as an ideal soft-tissue filler because it is abundant, readily available…
- Conditions
- Romberg's Disease, Craniofacial Microsomia, Lipodystrophy, Mixed Connective Tissue Disease
- Trial name
- NCT02494752
- Testing
- Fat graft enriched with ex vivo expanded stem cells, Fat graft not enriched with ex vivo expanded stem cells
- Volunteers
- 30 people
- Sponsor
- King Edward Medical University
Lipodystrophy
Short-term Effects of Leptin in People With Lipodystrophy
Background: Lipodystrophy is a condition where people do not have enough fat in the body. People with lipodystrophy can have problems such as diabetes or an enlarged liver.
- Trial name
- NCT01778556
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Partial Lipodystrophy
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
- Trial name
- NCT06484868
- Testing
- Metreleptin
- Where
- 12 sites in France, Germany and 2 more
- Volunteers
- 12 people
- Sponsor
- Amryt Pharma
HIV-1
Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent
The advent of highly active antiretroviral treatment has resulted in the survival into adolescence of an increasing proportion of infants and children with perinatal HIV infection in Senegal.
- Trial name
- NCT01771562
- Where
- 2 sites in Senegal
- Volunteers
- 330 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Lipodystrophy, Diabetes
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
Background: Generalized lipodystrophy can cause high blood fat levels and resistance to insulin. This can lead to health problems including diabetes.
- Conditions
- Lipodystrophy, Diabetes, Hyperlipidemia
- Trial name
- NCT02262832
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lipodystrophy, Generalized Lipodystrophy (GLD)
Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling
Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.
- Conditions
- Lipodystrophy, Generalized Lipodystrophy (GLD), Monogenic Obesity (MOB)
- Trial name
- NCT04710056
- Testing
- REGN4461
- Sponsor
- Regeneron Pharmaceuticals
Lipodystrophy
Leptin to Treat Lipodystrophy
This study will evaluate the safety and effectiveness of the leptin replacement therapy in treating lipoatrophy or lipodystrophy-a condition in which there is a total or partial loss of fat cells.
- Trial name
- NCT00005905
- Testing
- hu Leptin (A-100)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Lipodystrophy Acquired, Type1diabetes
Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes
This study evaluates the change of insulin resistance and glucose metabolism of patients with panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes with the treatment of cyclophosphamide.
- Trial name
- NCT03936829
- Testing
- Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Children's Hospital of Fudan University
Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent
[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy
This diagnostic study investigates the value of 68Ga-NOTA-GZP PET imaging in predicting and evaluating immunotherapy response in malignant tumors by enrolling pathologically confirmed patients scheduled for immunotherapy and…
- Conditions
- Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, Colorectal Cancer Screening
- Trial name
- NCT06982053
- Testing
- Received 68Ga-NOTA-GZP PET scanning
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
HIV Infections, HIV-Associated Lipodystrophy Syndrome
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
The purpose of this study is to assess the prevalence of metabolic and physical abnormalities in HIV infected (via mother-to-child transmission) and uninfected children and youth.
- Conditions
- HIV Infections, HIV-Associated Lipodystrophy Syndrome, HIV Lipodystrophy Syndrome, Lipodystrophy
- Trial name
- NCT00069004
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
The main purpose of this study is to evaluate the efficacy and safety of baricitinib in adult and pediatric Japanese participants with Nakajo-Nishimura Syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and…
- Conditions
- Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy, Aicardi Goutieres Syndrome
- Trial name
- NCT04517253
- Testing
- Baricitinib
- Where
- 5 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Lipodystrophy
Lipodystrophy Connect Patient Registry
Lipodystrophy Connect is an online survey tool designed to collect demographic data and health information from individuals with Lipodystrophy.
- Trial name
- NCT02577952
- Where
- United States
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- PatientCrossroads
Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
The study investigators' aim is to determine the long term safety and efficacy of Metreleptin (Myalept,) in promoting amelioration of metabolic abnormalities in patients with all forms of partial lipodystrophy.
- Conditions
- Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis, NAFLD
- Trial name
- NCT02654977
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan
Lipodystrophy
Leptin to Treat Lipodystrophy
This study will evaluate the safety and effectiveness of leptin replacement therapy in patients with lipodystrophy (also called lipoatrophy). Patients have a total or partial loss of fat cells.
- Trial name
- NCT00025883
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Partial Lipodystrophy
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
- Trial name
- METRE-PL (NCT05164341)
- Testing
- metreleptin
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 69 people
- Sponsor
- Chiesi Farmaceutici S.p.A.